Bio-Techne TECH Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash

Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies

RepligenRGEN

-$145K-104%

Thermo Fisher ScientificTMO

——

Other financials

Income statement

See full

Revenue$311.4M-1.5%

Gross profit$208.3M-2.9%

Operating income$75.5M+95.0%

Net income$51.0M+126%

EPS (diluted)$0.32+129%

Balance sheet

See full

Cash & equivalents$209.8M+49.2%

Total debt$290.3M-31.4%

Total equity$2.1B+3.3%

Total assets$2.6B-3.5%

Cash flow

See full

Operating cash flow$86.7M+111%

CapEx$9.1M-10.2%

Free cash flow$77.6M+150%

Valuation

See full

Market cap$9.07B-11.8%

Enterprise value$9.15B-13.6%

P/E60.6×+13.6×

P/S7.5×-1.0×

Profitability

See full

Gross margin65%-0.8pp

Operating margin14.2%-7.9pp

Net margin10.9%-6.7pp

FCF margin22.3%+4.0pp

Returns & leverage

See full

Return on equity6.5%-3.9pp

Debt / equity0.1×-0.1×

Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bio-Techne's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?: Bio-Techne (TECH) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of -$1.19M in Q1 2026.
How has Bio-Techne's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?: Bio-Techne's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash decreased by 9.9% year-over-year, from -$1.08M to -$1.19M.